StageGrant | Alive
About Virtual Incision
Virtual Incision is developing MIRA, a miniature and highly accessible RAS platform. MIRA is a space-saving surgical system with the goal of bringing the benefits of robotic-assisted surgery (RAS) to patients everywhere. The company was formerly known as Nebraska Surgical Solutions. Virtual Incision was founded in 2006 and is based in Lincoln, Nebraska.
Missing: Virtual Incision's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
ESPs containing Virtual Incision
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
Companies in this market provide software and hardware to provide real-time surgical guidance and workflow automation. These solutions are designed to improve the accuracy, efficiency, and reproducibility of surgeon performance, by creating systemic methods for process improvement and quality control in surgery.
Virtual Incision named as Challenger among 15 other companies, including Caresyntax, Iterative Health, and Theator.
Missing: Virtual Incision's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Research containing Virtual Incision
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Virtual Incision in 1 CB Insights research brief, most recently on Apr 22, 2020.
Expert Collections containing Virtual Incision
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Virtual Incision is included in 6 Expert Collections, including Robotics.
This collection includes startups developing autonomous ground robots, unmanned aerial vehicles, robotic arms, and underwater drones, among other robotic systems. This collection also includes companies developing operating systems and vision modules for robots.
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)
This collection includes public and private companies, as well as startups, that market software solutions to healthcare provider organizations.
Clinical Encounter Tech
Virtual Incision Patents
Virtual Incision has filed 20 patents.
The 3 most popular patent topics include:
- Surgical removal procedures
- Digestive system surgery
- Surgical procedures and techniques
Robot kinematics, Robots, Robotic manipulators, Robot control, Industrial robots
Robot kinematics, Robots, Robotic manipulators, Robot control, Industrial robots
Latest Virtual Incision News
Feb 28, 2023
News provided by Share this article FDA decision supported by an interim clinical study report on patient safety GRAND RAPIDS, Mich., Feb. 28, 2023 /PRNewswire/ -- cultivate(MD) Capital Funds LP , funds that are focused on investments into early-stage healthcare companies with innovative technologies, announced today that one of their portfolio companies, Lincoln, Nebraska-based Virtual Incision Corporation , has completed its U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) clinical study. Virtual Incision Corporation is a medical device company developing the world's first miniaturized robotic-assisted surgery (RAS) system. The study was designed to evaluate the company's MIRA Surgical System for use in bowel resection procedures and it is an important achievement towards bringing new technologies to hospitals and their surgical robotics programs regardless of the site of care. The surgical cases were completed at three hospitals across the country. Patients who participated in the study were followed after their procedure to fulfill study requirements. The complete data will be correlated and submitted to the FDA as part of the company's De Novo request for market authorization. Virtual Incision is the first RAS developer to complete a U.S. IDE study to support a De Novo request in bowel resection. cultivate(MD) is a medical device venture capital fund dedicated to bringing emerging health care innovations to market. "The investigators are very encouraged by our experiences trialing the MIRA Surgical System," said Michael A. Jobst, MD, colorectal surgeon. "Across the sites, we've seen MIRA efficiently integrate into existing RAS programs and witnessed how it is mobile enough for use in any operating room. Some sites have even completed multiple cases in a single day. We are eager to fulfill the clinical requirements of the study in hopes that MIRA can help expand RAS access to more patients in the future." R. Sean Churchill, MD, MBA, Executive Director of Genesis Innovation Group said, "cultivate(MD) Capital Funds are proud to have partnered with Virtual Incision Corporation over the past four years. The ability of the MIRA Surgical System to bring robotic surgery to every hospital, not just large research centers, sets Virtual Incision apart from other robotic manufacturers. cultivate(MD) immediately recognized the unmet need for more cost effective and versatile robotics in the operating room and is a firm supporter of bringing this technology into practice. The MIRA platform has numerous products to address all aspects of abdominal surgery and stands to be the leader in minimally invasive robotic surgery." There are 5 million Americans who undergo abdominal soft tissue procedures annually, however, more than 90 percent go without access to RAS. If authorized by the FDA, MIRA's miniaturized, strong, and easy-to-use design could potentially increase the overall availability of RAS. It has the potential to integrate into any facility or operating room by serving as a complement to the existing mainframe RAS systems, or by expanding into new sites of care and geographies as a standalone. Virtual Incision aims to increase patient access through a clinically, operationally, and economically sound platform available to all providers. "Completing MIRA's IDE clinical study is a critical milestone in our journey to making RAS more accessible," said John Murphy, president and chief executive officer of Virtual Incision. "Currently, less than 10 percent of the 90,000 operating rooms in the U.S. are equipped with mainframe RAS systems. Beyond the incredible progress of the industry pioneer, it's still in the early days of the adoption of soft tissue surgical robotics. Our ultimate goal is to develop world-class miniature RAS devices with the required strength and dexterity to enable positive clinical outcomes for a broad range of procedure types." About Virtual Incision Virtual Incision is on a mission to simplify robotic-assisted surgery (RAS), so more patients and their surgeons can access its benefits every day. Headquartered in Lincoln, Nebraska, and holding over 200 patents and patent applications, the company is developing MIRA, the first-of-its-kind miniature RAS platform. Virtual Incision's goal is to make every operating room RAS-ready. About cultivate(MD) Capital Funds As a medical device venture capital fund, cultivate(MD) is dedicated to bringing emerging health care innovations to market, with a special focus on medical device and orthopedic technologies. cultivate(MD) is focused on investing in early stage healthcare companies with innovative technologies that have demonstrated evidence of effectiveness. For more information, visit: https://genesisinnovationgroup.com/ Cautionary Note Regarding Forward-Looking Statements This communication contains statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations, assumptions, and other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date on which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. SOURCE cultivate(MD)
Virtual Incision Frequently Asked Questions (FAQ)
When was Virtual Incision founded?
Virtual Incision was founded in 2006.
Where is Virtual Incision's headquarters?
Virtual Incision's headquarters is located at 2125 Transformation Drive, Lincoln.
What is Virtual Incision's latest funding round?
Virtual Incision's latest funding round is Grant.
How much did Virtual Incision raise?
Virtual Incision raised a total of $114.13M.
Who are the investors of Virtual Incision?
Investors of Virtual Incision include NASA, Bluestem Capital Partners, Baird Capital Partners, Endeavour Vision, PrairieGold Venture Partners and 6 more.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.